Corporate Banner
Satellite Banner
Pharma Outsourcing
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Cytovance Biologics and Pamlico Biopharma Announce Agreement

Published: Friday, February 21, 2014
Last Updated: Thursday, February 20, 2014
Bookmark and Share
Development and cGMP manufacturing agreement to advance the treatment of Streptococcus pneumoniae infections.

Cytovance Biologics, Inc. has announced that they have entered into a development and manufacturing agreement with Pamlico Biopharma, Inc., an Oklahoma City-based clinical stage bio-pharmaceutical company.

Pamlico Biopharma has developed a group of three human IgG monoclonal antibodies intended for the treatment of Streptococcus pneumoniae infections.

Pamlico has contracted Cytovance Biologics as its CMO to develop a production cell line from the protein’s amino acid sequence for GMP manufacture of phase I clinical material.

“With this agreement, Pamlico Biopharma has reached a milestone in the development of a therapeutic antibody product for the treatment of Streptococcus pneumoniae, a leading cause of Severe Community Acquired Pneumonia (SCAP) which can lead to hospitalization and death,” said Clayton Duncan, CEO of Pamlico Biopharma, Inc.

“Cytovance’s state-of-the-art facilities and experienced staff are prepared to deliver the highest quality of development and manufacturing services for Pamlico Bioparma,” said Darren Head, President and Chief Executive Officer of Cytovance Biologics.

Head continued, “We are delighted to be working with such an innovative company that uses technologies from the Oklahoma Medical Research Foundation and advance the treatment of Streptococcus pneumoniae infections that are associated with over 50,000 deaths annually.”


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,100+ scientific posters on ePosters
  • More than 4,500+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Cytovance Biologics Selected for GMP Manufacture of AM0010
Provides drug product for Phase I trials.
Tuesday, July 01, 2014
Cytovance and Precision Biologics Announce Extension of Manufacturing Agreement
Extension of cGMP manufacturing agreement for NEO-102 drug product.
Saturday, March 29, 2014
Scientific News
Investigational Malaria Vaccine Protects Healthy U.S. Adults
Researchers at NIH have found that the malaria vaccine protected a small number of healthy, malaria-naïve adults in the U.S. from infection for more than one year after immunization.
AACR 2016: Cancer Immunotherapy and Beyond
At this year's meeting there was a palpable buzz around subjects ranging from microbiomics to the tumor microenvironment and cancer vaccines, big data to in vitro and in vivo modeling and drug delivery (to name just a few).
New Database for Sharing MS Clinical Trial Data
A new database containing nearly 2500 patient records from the placebo arms of nine multiple sclerosis (MS) clinical trials is now available for research by qualified investigators.
Study Finds Factors That May Influence Influenza Vaccine Effectiveness
Researchers at NIH have suggested that the long-held approach to predicting seasonal influenza vaccine effectiveness may need to be revisited.
BMS’s Opdivo Clinical Trial Shows Promise
Safety profile of the combination regimen from CheckMate -069 was consistent with previously reported studies and adverse events were managed using established safety algorithms.
Treatment of Common Prostate Cancer
Researchers at UTSW have found that the prostate cancer treatments suppress immune response and may promote relapse.
Cancer Drug Could Treat Blood Vessel Deformities
A drug currently being trialled in cancer patients could also be used to treat an often incurable condition that can cause painful blood vessel overgrowths inside the skin.
Structure of Crucial Enzyme Identified
Researchers at UTSW have determined the atomic structure of an enzyme that plays an essential role in cell division and better treatment of cancer.
New Immunotherapy Trial for Type 1 Diabetes
The search for a treatment for Type 1 diabetes (T1D) - which affects over 400,000 people in the UK – will be stepped up with the start of a new phase one clinical trial at Guy’s Hospital in London.
Recruitment of First Patient in Clinical Study
Company has announced recruitment of first patient in clinical study assessing Visco-ease with Beatson Cancer Centre for the treatment of RIX.
Scroll Up
Scroll Down
SELECTBIO

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,100+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,500+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!